国家医保局： 第十一批药品集采工作已启动

Group 1 - The National Medical Insurance Administration (NMIA) has initiated the 11th batch of drug procurement, focusing on optimizing procurement rules while ensuring clinical stability, quality assurance, and preventing price collusion [1][2] - Since 2018, the NMIA has conducted ten batches of centralized procurement covering 435 drug varieties, which has effectively reduced drug prices and improved accessibility for the public [1][2] - The 11th batch aims to include 55 drug varieties across various therapeutic areas, maintaining the principle of excluding new drugs from procurement and aligning with the medical insurance catalog negotiations [2] Group 2 - The NMIA is advancing payment reform during the 14th Five-Year Plan, transitioning from a retrospective payment system to a prospective one, and from project-based payments to disease-based payments [3] - By 2024, the basic medical insurance fund expenditure is projected to reach 2.98 trillion yuan, with a 5% decrease in patient out-of-pocket expenses year-on-year [3] - The NMIA is also enhancing the payment reform by developing version 2.0 of the disease-based payment scheme and establishing supporting mechanisms to promote medical technology innovation [3]